CytomX Therapeutics (CTMX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

CytomX Therapeutics Revenue Highlights


Latest Revenue (Y)

$101.21M

Latest Revenue (Q)

$25.11M

CytomX Therapeutics Revenue by Period


CytomX Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$101.21M90.38%
2022-12-31$53.16M-23.59%
2021-12-31$69.57M-30.68%
2020-12-31$100.36M74.58%
2019-12-31$57.49M-3.38%
2018-12-31$59.50M-16.92%
2017-12-31$71.62M376.12%
2016-12-31$15.04M95.06%
2015-12-31$7.71M51.90%
2014-12-31$5.08M471.73%
2013-12-31$888.00K-

CytomX Therapeutics generated $101.21M in revenue during NA 2023, up 90.38% compared to the previous quarter, and up 170.10% compared to the same period a year ago.

CytomX Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$25.11M-39.43%
2024-03-31$41.46M55.83%
2023-12-31$26.61M0.85%
2023-09-30$26.38M6.71%
2023-06-30$24.72M5.21%
2023-03-31$23.50M2384.04%
2022-12-31$946.00K-94.41%
2022-09-30$16.91M-6.88%
2022-06-30$18.16M6.00%
2022-03-31$17.14M-13.13%
2021-12-31$19.73M12.17%
2021-09-30$17.59M7.98%
2021-06-30$16.29M1.98%
2021-03-31$15.97M-2.46%
2020-12-31$16.37M-7.95%
2020-09-30$17.79M7.11%
2020-06-30$16.61M-66.51%
2020-03-31$49.59M499.02%
2019-12-31$8.28M-22.71%
2019-09-30$10.71M18.85%
2019-06-30$9.01M-69.43%
2019-03-31$29.48M157.04%
2018-12-31$11.47M-8.30%
2018-09-30$12.51M-41.38%
2018-06-30$21.34M50.44%
2018-03-31$14.18M-47.61%
2017-12-31$27.07M12.13%
2017-09-30$24.14M175.87%
2017-06-30$8.75M-24.89%
2017-03-31$11.65M85.79%
2016-12-31$6.27M81.59%
2016-09-30$3.45M11.64%
2016-06-30$3.09M39.18%
2016-03-31$2.22M11.82%
2015-12-31$1.99M2.53%
2015-09-30$1.94M-5.09%
2015-06-30$2.04M17.28%
2015-03-31$1.74M-6.39%
2014-12-31$1.86M-2.82%
2014-09-30$1.92M-

CytomX Therapeutics generated $25.11M in revenue during Q2 2024, up -39.43% compared to the previous quarter, and up 106.88% compared to the same period a year ago.

CytomX Therapeutics Revenue Breakdown


CytomX Therapeutics Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceSep 18Jun 18Mar 18
License And Service$2.80M--
Amgen Other Products-$4.20M$4.40M
E G F R Products-$42.30M$43.70M

CytomX Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 18: License And Service (100.00%).

CytomX Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountrySep 18Jun 18Mar 18
License And Service$2.80M--
E G F R Products-$42.30M$43.70M
Amgen Other Products-$4.20M$4.40M

CytomX Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 18: License And Service (100.00%).

CytomX Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
CTMXCytomX Therapeutics$101.21M$25.11M
SPROSpero Therapeutics$96.73M$10.20M
ASMBAssembly Biosciences$7.16M$5.79M
NXTCNextCure--
TILInstil Bio--
NLTXNeurogene--
ACHLAchilles Therapeutics--
NUVBNuvation Bio-$1.44M

CTMX Revenue FAQ


CytomX Therapeutics's yearly revenue for 2023 was $101.21M, representing an increase of 90.38% compared to 2022. The company's yearly revenue for 2022 was $53.16M, representing a decrease of -23.59% compared to 2021. CTMX's yearly revenue for 2021 was $69.57M, representing a decrease of -30.68% compared to 2020.

CytomX Therapeutics's quarterly revenue for Q2 2024 was $25.12M, a -39.43% decrease from the previous quarter (Q1 2024), and a 1.58% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $41.46M, a 55.83% increase from the previous quarter (Q4 2023), and a 76.45% increase year-over-year (Q1 2023). CTMX's quarterly revenue for Q4 2023 was $26.61M, a 0.85% increase from the previous quarter (Q3 2023), and a 2712.58% increase year-over-year (Q4 2022).

CytomX Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 45.48%, and for the last 5 years (2019-2023) was 76.06%.